The HCPLive Rheumatology condition center page is a comprehensive resource for clinical news and insights on rheumatologic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for arthritis, gout, nr-AxSpA, and more.
September 17th 2024
Better known as brittle bone disease, osteogenesis imperfecta can cause severe respiratory distress at birth and longterm effect to respiratory function. Morello shares his team's research into the cause of this effect.
Collaborating Across the Continuum™: The Role of Multidisciplinary Care in the Management of Patients with Exocrine Pancreatic Insufficiency
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
October 16, 2024
Register Now!
Tackling Inequities in IBD: Inclusive Solutions for Elevated Patient Care
October 26, 2024
Register Now!
6th Annual Advanced Practice Collaborative
View More
SimulatED™: Personalizing Treatment Choices to Achieve Glycemic and Weight Management Goals
View More
Cases and Conversations™: Keeping Up with Novel Approaches to Managing ANCA-Associated Vasculitis
November 18, 2024
Register Now!
Shaping the Management of COPD with Biologic Therapy
View More
Elevating Care for PAH: Applying Recommended Management Approaches to Maximize Outcomes
View More
Clinical Consultations™: Managing Depressive Episodes in Patients with Bipolar Disorder Type II
View More
Expert Illustrations & Commentaries™: Exploring the Role of Novel Agents for the Management of IgA Nephropathy
View More
Medical Crossfire®: Understanding the Advances in Bipolar Disease Treatment—A Comprehensive Look at Treatment Selection Strategies
View More
'REEL’ Time Patient Counseling: The Diagnostic and Treatment Journey for Patients With Bipolar Disorder Type II – From Primary to Specialty Care
View More
‘REEL’ Time Patient Counseling™: Navigating the Complex Journey of Diagnosing and Managing Fabry Disease
View More
Expert Illustrations & Commentaries™: Envisioning Novel Therapeutic Approaches to Managing ANCA-associated Vasculitis
View More
Clinical ShowCase™: Finding the Best Path Forward for Patients with COPD
View More
A Tethered Approach to Type 2 Diabetes Care – Connecting Insulin Regimens with Digital Technology
View More
Surv.AI Says™: What Clinicians and Patients Are Saying About Glucose Management in the Technology Age
View More
Clinical ShowCase™: Forming a Personalized Treatment Plan for a Patient With ANCA-Associated Vasculitis
View More
Addressing Healthcare Inequities: Tailoring Cancer Screening Plans to Address Inequities in Care
View More
SimulatED™: Diagnosing and Treating Alzheimer’s Disease in the Modern Era
View More
Patient, Provider & Caregiver Connection™: Implementing an Effective Management Plan to Improve Outcomes in IgA Nephropathy
View More
Remission after conventional treatment for RA is attainable
October 2nd 2009Sustained disease-modifying antirheumatic drug (DMARD)-free remission occurs in about 10% of patients with rheumatoid arthritis (RA). It can be predicted by several clinical variables that are assessed routinely in outpatient clinics.
Tumor necrosis factor inhibitors used for RA at lower threshold
October 2nd 2009Tumor necrosis factor (TNF) inhibitors are being used for rheumatoid arthritis (RA) more aggressively and at a lower level of disease activity than in the past. Their use is greater in patients with established RA than in those with early RA.
Prevent patellofemoral pain to prevent knee osteoarthritis?
October 2nd 2009Persons who have patellofemoral pain (PFP) exhibit higher peak levels of patellofemoral stress than those who do not, according to work conducted at the University of Southern California's Musculoskeletal Biomechanics Research Laboratory (MBRL), and a long-term history of PFP in older adults yields a higher probability that patellofemoral osteoarthritis (OA) will occur.
Musculoskeletal practice guidelines for general practitioners
September 30th 2009New evidence-based musculoskeletal disease prevention and treatment guidelines for general practitioners have been issued by the Royal Australian College of General Practitioners (RACGP). Rheumatoid arthritis (RA), juvenile idiopathic arthritis, and osteoarthritis guidelines have been released, and osteoporosis guidelines were expected to be available soon.
Signaling Molecules May Limit Bone Destruction and Bone Loss from RA
September 29th 2009Researchers have discovered a new way to use the role of signaling molecules to inhibit another complex that plays a key role in the ‘turning on’ of genes “that cause the stem cell precursors of osteoclasts to mature and start eating bone,” a discovery that may lead to the formation of new rheumatoid arthritis and osteoporosis drugs.
New Genetic Test Will Enable Early Detection - and Treatment - of Psoriatic Arthritis
September 16th 2009A new genetic test that can detect the presence of psoriatic arthritis (PsA) was launched on Tuesday, September 15, that may enable physicians to administer early treatment, lessening joint damage and decreasing inflammation, therefore reducing symptoms.
Stress in the Workplace may Decrease an Individual's Risk for Developing Rheumatoid Arthritis
September 10th 2009Psychosocial work stress has been previously associated with an increased risk for cardiovascular disease. New research now reveals that high work stress may actually decrease an individual's chance of developing inflammatory conditions, including rheumatoid arthritis.
Arthritis in a patient with severe psoriasis: Narrowing the differential
August 29th 2009An 84-year-old woman presented with pain and swelling in her knees and hands. She had a history of severe psoriasis and osteoarthritis. How can you make a differential diagnosis when OA may coexist with rheumatoid arthritis, psoriatic arthritis, OA, and crystal arthritis? Read on to find out.
Majority of Chronic Pain Patients Improperly Use Prescribed Medications
August 27th 2009An Ameritox study found that of 938,586 urine toxicology tests administered to chronic pain patients over a three-year period, 11% detected major illicit drugs and 29% had a medication in their system that the patient's doctor was likely unaware of.
Updated H1N1 (swine) flu advisory for persons with lupus
August 27th 2009The precautionary recommendations for the H1N1 (swine) flu in persons with lupus currently are not different from those for the general public, according to the Lupus Foundation of America (LFA). However, because persons with lupus often are at increased risk for infections, especially if they are taking immunosuppressive agents, they should be particularly vigilant about taking the generally recommended precautions.
Hepatitis screening not useful for patients with polyarthritis
August 25th 2009The seroprevalence of hepatitis is no higher in patients with recent-onset polyarthritis than in the general population. Therefore, screening patients for hepatitis B virus (HBV) and hepatitis C virus (HCV) infection when evaluating them for polyarthritis suggestive of rheumatoid arthritis (RA) is not useful.
Social activity in older persons slows motor function decline
August 25th 2009In older persons who do not have dementia, stroke, or Parkinson disease, a lower frequency of participation in social activity is associated with more rapid motor function decline. Conversely, participation in a broad spectrum of late-life activities results in positive health outcomes.
Laboratory tests help identify, but do not confirm, RA
August 25th 2009In most patients with rheumatoid arthritis (RA), the results of common laboratory testing-rheumatoid factor (RF), erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) level-are abnormal and may be used to support the diagnosis. However, a substantial proportion of patients with RA have normal test results.
Do changes in femoral neck geometry predict hip osteoarthritis?
August 25th 2009A wider femoral neck and more medial centroid position of bone mineral in the femoral neck are associated with an increased risk of prevalent, incident, and progressive radiographic hip osteoarthritis (RHOA). These differences are detectable early in the natural history of hip OA.
FDA now Requires Stronger Warning Labels for Tumor-necrosis Factor-alpha Blockers
August 21st 2009The FDA is now requiring that stronger product warnings be included in the prescribing information of tumor necrosis factor-alpha blockers because of an increased risk of cancer in the children and adolescents who take them.
Established and Novel Treatments for Lupus
August 4th 2009Although many medications are used for the management of systemic lupus erythematosus (SLE) and its complications, only aspirin, corticosteroids, and the antimalarial drug hydroxychloroquine (HCQ) are specifically approved by the FDA.1 Most other medications used for SLE treatment are commercially available off label (Table 1), usually borrowed from cancer or transplant regimens. In some cases, medications have been approved for a specific clinical manifestation seen in both idiopathic disease and SLE, such as bosentan for pulmonary hypertension.
Evaluating cardiovascular risk in rheumatoid arthritis
August 4th 2009There have been significant advances in the management of rheumatologic disorders with the availability of newer disease-modifying drugs and biologic agents. However, cardiovascular disease (CVD) morbidity and mortality remain significantly increased in patients with rheumatologic disorders, especially rheumatoid arthritis (RA)1-4 and systemic lupus erythematosus (SLE).